Randomised, placebo-controlled, three-arm parallel-group, double-blind
Randomised, placebo-controlled, three-arm parallel-group, double-blind, multicentre, national clinical phase II study to evaluate the efficacy, safety, and tolerability of intravenous 3 and 6 g/m² treosulfan given every 6 weeks in patients with secondary progressive and progressive relapsing multiple sclerosis.
What it found
Stopped
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Treosulfan
DNA cross-linking agent
Loading reviews and guidelines…
History
Started
Nov 2006
Assembled by software from public sources.